Culturing of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine Cells
First Claim
Patent Images
1. A method for producing cells expressing markers characteristic of pancreatic endocrine cells from pluripotent stem cells, comprising the steps of:
- a. culturing pluripotent stem cells;
b. differentiating the pluripotent stem cells into cells expressing markers characteristic of pancreatic foregut precursor cells; and
c. differentiating the cells expressing markers characteristic of pancreatic foregut precursor cells into cells expressing markers characteristic of pancreatic endocrine cells by treatment with at least one medium supplemented with an ALK5 inhibitor, or a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine and mixtures thereof, or both ALK5 inhibitor and thyroid hormone, and culturing at the air-liquid interface.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells expressing PDX1, NKX6.1, and HB9 by culturing in a culture vessel at the air-liquid interface. The invention also provides for in vivo maturation of cells cultured at the air-liquid interface.
37 Citations
96 Claims
-
1. A method for producing cells expressing markers characteristic of pancreatic endocrine cells from pluripotent stem cells, comprising the steps of:
-
a. culturing pluripotent stem cells; b. differentiating the pluripotent stem cells into cells expressing markers characteristic of pancreatic foregut precursor cells; and c. differentiating the cells expressing markers characteristic of pancreatic foregut precursor cells into cells expressing markers characteristic of pancreatic endocrine cells by treatment with at least one medium supplemented with an ALK5 inhibitor, or a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine and mixtures thereof, or both ALK5 inhibitor and thyroid hormone, and culturing at the air-liquid interface. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 95, 96)
-
- 25. A method of producing cells expressing markers characteristic of pancreatic endocrine cells comprising differentiating cells expressing markers characteristic of foregut endoderm cells into cells expressing markers characteristic of pancreatic endocrine cells by treatment with at least one medium supplemented with an ALK5 inhibitor, or a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine and mixtures thereof, or both ALK5 inhibitor and thyroid hormone, while culturing at the air-liquid interface.
-
40. A method of inducing PDX1, NKX6.1, and HB9 expression in cells derived from pluripotent stem cells comprising:
-
a. culturing pluripotent stem cells; b. differentiating the pluripotent stem cells into cells expressing markers characteristic of pancreatic foregut precursor cells; and c. differentiating the cells expressing markers characteristic of pancreatic foregut precursor cells into cells expressing PDX1, NKX6.1, and HB9 by treatment with a medium supplemented with an ALK5 inhibitor, or a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine and mixtures thereof, or both ALK5 inhibitor and thyroid hormone, and culturing at the air-liquid interface. - View Dependent Claims (41, 42, 43, 44)
-
-
45. An in vitro cell culture for differentiating cells at an air-liquid interface comprising:
-
a. a culture vessel; b. a volume of differentiation medium within said vessel sufficient to fill only a portion of the volume of said vessel; c. air within said vessel that fills a portion of said vessel adjoining said medium; d. a porous substrate located at the interface between said medium and said air; and e. cells derived from pluripotent stem cells disposed upon the surface of said substrate such that said medium contacts only a portion of the surface of said cells. - View Dependent Claims (46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)
-
-
80. A medium useful for inducing differentiation in cells derived from pluripotent stem cells comprising a growth medium supplemented with:
-
a. an ALK5 inhibitor selected from the group consisting of;
ALK5 inhibitor II, ALK5i, SD208, TGF-B inhibitor SB431542, ITD-1, LY2109761, A83-01, LY2157299, TGF-β
receptor inh V, TGF-β
receptor inh I, TGF-β
receptor inh I TGF-β
receptor inh IV, TGF-β
receptor inh VII, TGF-β
receptor inh VIII, TGF-β
receptor inh II, TGF-β
receptor inh VI, TGF-β
receptor inh III; andb. a BMP Receptor Inhibitor selected from LDN-193189, Noggin or Chordin; - View Dependent Claims (81, 82, 83, 84, 85, 86)
-
-
87. A medium useful for inducing differentiation in cells derived from pluripotent stem cells comprising a growth medium supplemented with:
-
a. an ALK5 inhibitor selected from the group consisting of;
ALK5 inhibitor II, ALK5i, SD208, TGF-B inhibitor SB431542, ITD-1, LY2109761, A83-01, LY2157299, TGF-β
receptor inh V, TGF-β
receptor inh I, TGF-β
receptor inh I TGF-β
receptor inh IV, TGF-β
receptor inh VII, TGF-β
receptor inh VIII, TGF-β
receptor inh II, TGF-β
receptor inh VI, TGF-β
receptor inh III;b. a thyroid hormone selected from the group consisting of triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine and mixtures thereof; and c. a SHH signaling pathway antagonist selected from SANT-1 or HPI-1. - View Dependent Claims (88, 89, 90, 91, 92)
-
-
93. An in vitro cell culture comprising a population of differentiated pluripotent stem cells expressing markers characteristic of pancreatic endocrine cells wherein at least thirty percent of said differentiated cells express NKX6.1 and insulin.
-
94. An in vitro cell culture comprising a population of differentiated pluripotent stem cells expressing markers characteristic of pancreatic endocrine cells wherein at least thirty percent of said differentiated cells express NKX6.1 and chromagranin.
Specification